Literature DB >> 8147750

Involuntary movements and AIDS: report of seven cases and review of the literature.

J P De Mattos1, A L Rosso, R B Corrêa, S Novis.   

Abstract

We studied 1086 AIDS patients in the last six years. Of these 389 (35.82%) had neurological manifestation and 7 (1.8%) male patients had abnormal involuntary movements (parkinsonism in 3, hemichorea-hemiballism in 2, spinal myoclonus in 1 and rubral tremor in another). All patients were men, 5 white and 2 black. Four were homosexual, 2 drug-users and 1 bisexual. The mean age was 33.14 years. The time between AIDS diagnosis and the onset of movement disorders was 23.8 months in 5 patients and in 2 it was the first symptom. The parkinsonian patients did not show any opportunistic infection in connection with the neurological symptoms but in the remaining four cases this relationship was suggested. The data showed that not only the opportunistic infection but also the AIDS virus may play an important role on the development of involuntary movements.

Entities:  

Mesh:

Year:  1993        PMID: 8147750     DOI: 10.1590/s0004-282x1993000400011

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  3 in total

1.  Progressive Degeneration and Adaptive Excitability in Dopamine D1 and D2 Receptor-Expressing Striatal Neurons Exposed to HIV-1 Tat and Morphine.

Authors:  Arianna R S Lark; Lindsay K Silva; Sara R Nass; Michael G Marone; Michael Ohene-Nyako; Therese M Ihrig; William D Marks; Viktor Yarotskyy; A Rory McQuiston; Pamela E Knapp; Kurt F Hauser
Journal:  Cell Mol Neurobiol       Date:  2022-06-13       Impact factor: 5.046

Review 2.  HIV-related movement disorders: epidemiology, pathogenesis and management.

Authors:  Francisco Cardoso
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

3.  Sexual and Gender Minority Health in Neurology: A Scoping Review.

Authors:  Nicole Rosendale; Jeffrey O Wong; Jason D Flatt; Evans Whitaker
Journal:  JAMA Neurol       Date:  2021-06-01       Impact factor: 29.907

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.